New agents in the treatment of MDS.
Malignant Hematology Division, H. Lee Moffitt Cancer Center and Research Institute, USA.
Alan F
AF
List
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D000077209:Decitabine; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy*; D011237:Predictive Value of Tests; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D007211:Indoles; C499748:SCIO-469; D013792:Thalidomide; D000077209:Decitabine; D000077269:Lenalidomide; D001374:Azacitidine